Elite Pharmaceuticals (ELI) Announces Strategic Alliance with Dr. Veerappan Subramanian
Elite Pharmaceuticals (AMEX: ELI) has commenced a Strategic Alliance with Dr. Veerappan Subramanian under which Dr. Subramanian has joined Elite's Board of Directors and will serve as strategic advisor to Elite on the research, development and commercialization of Elite's existing pipeline, including its two lead pain products. As part of the Strategic Alliance with Elite, VGS Pharma LLC has made a $2 million equity investment in Elite.
Dr. Subramanian brings extensive experience in generics formulation and management, having been responsible for the development and FDA approval of over 150 specialty and generic drug products during his 33 years in the pharmaceutical industry.
Dr. Subramanian brings extensive experience in generics formulation and management, having been responsible for the development and FDA approval of over 150 specialty and generic drug products during his 33 years in the pharmaceutical industry.
You May Also Be Interested In
- Fred's, Inc. (FRED) Named Steven R. Fitzpatrick to Board of Directors
- Midway Gold (MDW) CEO Wolfus Resigns for Health Issues; Successor Named
- Barclays Maintains an 'Equalweight' on Brookfield Properties (BPO); Corporate Evolution
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
